Global Chordoma
Disease Therapeutics Market, by Drug Class (Antimetabolites, Anthracycline,
VEGFR Inhibitors, EGFR Inhibitor, and Others), by Treatment Type (Chemotherapy,
Targeted Therapy, Radiation Therapy, and Others), by End User (Hospitals,
Clinics, Oncology Centers, and Others), and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa), is expected to be
valued at US$ 5,296.31 million in 2020
and is expected to exhibit a CAGR of 6.7% over the forecast period (2019-2027),
as highlighted in a new report published by Coherent Market Insights.
Major players operating in the
chordoma disease therapeutics market, research organizations, and non-profit
organizations are collaborating to enhance their research and development
activities, in order to develop advanced treatment for chordoma, which is
expected to boost the market growth over the forecast period. For instance, in
June 2019, The Cancer Research Institute (CRI) and Chordoma Foundation entered
into a research partnership to advance treatment options for chordoma. Through
this partnership, both the organizations will fund researches that have the
potential to bring the benefits of immunotherapy to patients with chordoma.
Global Chordoma Disease
Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic
Due to the COVID-19 outbreak, all
the major events held by the National Brain Tumor Society (NBTS) scheduled in
the month of March, April and May, have been moved to virtual platforms to
ensure the well-being of all the patients as well as healthcare providers.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3979
The clinical trials associated
with brain tumors are being conducted with certain safety measures taken by the
healthcare facilities which include
The healthcare providers are
conducting patient consents through phone or video conferences.
The patients receive a phone call
for the screening of COVID-19 symptoms before the scheduled in-person visits
The assessments of the studies
are being done in single outpatient areas.
Browse 27 Market Data Tables and
26 Figures spread through 201 Pages and in-depth TOC on “Chordoma Disease
Therapeutics Market”- Global Forecast to 2027, by Drug Class (Antimetabolites,
Anthracycline, VEGFR Inhibitors, EGFR Inhibitor, and Others), by Treatment Type
(Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), by End User
(Hospitals, Clinics, Oncology Centers, and Others), and by Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
Key players operating in the
market are focused on various inorganic growth strategies such as partnerships
and agreements, in order to expand their product offerings in the market. For
instance, in May 2018, mAbxience, a company specialized in monoclonal antibody
biosimilars, and Amneal Pharmaceuticals, Inc. signed an exclusive licensing and
supply agreement for mAbxience´s bevacizumab, a biosimilar candidate for
Avastin. Through this agreement, Amneal Pharmaceuticals, Inc. gained the rights
to commercialize mAbxience´s bevacizumab in the U.S.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/chordoma-disease-therapeutics-market-3979
Key Takeaways of the Global
Chordoma Disease Therapeutics Market:
The global chordoma disease
therapeutics market is expected to exhibit a CAGR of 6.7% over the forecast
period, owing to increased product launches and approvals, and increasing
prevalence of chordoma. For instance, in September 2016, the Bone Cancer
Research Trust estimated that around 35 people are diagnosed with chordoma
every year, in the U.K. and Ireland.
Among drug class, VEGFR inhibitor
segment held the largest market share in 2019, owing to increasing launches of
new drugs in the market. For instance, in December 2019, Daiichi Sankyo
Company, Limited, a pharmaceutical company, launched bevacizumab BS for
intravenous drip infusions in Japan.
Among treatment type, targeted
therapy segment held largest market share in 2019, owing to increased launches
and approvals generic drugs for chordoma treatment. For instance, in May 2019,
Teva Pharmaceutical Industries Ltd. launched the generic version of Tarceva
(erlotinib) tablets in the U.S.
Companies operating in the global
chordoma disease therapeutics market include GlaxoSmithKline Plc, Bavarian
Nordic A/S, Boehringer Ingelheim International GmbH, Pfizer, Inc., Merck &
Co., Inc., Sanofi SA, Astellas Pharma Inc., AstraZeneca plc, Amgen, Inc.,
Bristol-Myers Squibb and Company, Novartis International AG, Bayer AG, Dr.
Reddy’s Laboratories Ltd., and Mylan N.V.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3979
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment